MVIC and Upperton Launch Integrated Development Pathway

MVIC and Upperton Pharma Solutions have launched a strategic collaboration intended to provide pharmaceutical and biotech companies with an integrated drug development pathway, according to Contractpharma.

The collaboration brings together activities spanning early discovery, formulation development, preclinical support and clinical trial manufacturing. Contractpharma reported that the pathway is aimed at supporting companies across these stages of development within a coordinated offering.

Development activities brought together

According to Contractpharma, the MVIC and Upperton collaboration covers early discovery alongside formulation development, preclinical support and clinical trial manufacturing. The announcement positions the arrangement as an integrated pathway for pharmaceutical and biotech companies working through development activities.

For medical and pharmaceutical sales professionals, the launch highlights a collaboration centered on the handoffs between discovery, formulation, preclinical work and clinical trial manufacturing. The companies’ stated focus is on bringing those areas together through the new pathway.

Relevance for biotech and pharmaceutical teams

Contractpharma identified pharmaceutical and biotech companies as the intended users of the integrated development pathway. The collaboration creates a shared market-facing proposition from MVIC and Upperton Pharma Solutions around development support and clinical trial manufacturing.

Sales professionals tracking outsourced development and manufacturing activity can note the scope described in the announcement: early discovery, formulation development, preclinical support and clinical trial manufacturing. The reported collaboration places those capabilities within a single strategic arrangement.

What was announced

• MVIC and Upperton Pharma Solutions entered a strategic collaboration.
• The collaboration is intended to provide an integrated drug development pathway.
• The pathway spans early discovery, formulation development, preclinical support and clinical trial manufacturing.
• Pharmaceutical and biotech companies are the stated audience for the offering.

Contractpharma reported the launch as an integrated development initiative involving MVIC and Upperton Pharma Solutions.